HETEROGENEOUS TARGETABLE KRAS/MSI/BRAF · Inventory First KRAS/NRAS / MSI-H / BRAF V600E / HER2 γ₁ = 14.134725141734693 · CRC · KRAS/BRAF · MMR/MSI · CEA · bevacizumab CANCER BOARD NEURO
COLORECTAL · CRC
Driver
KRAS/NRAS / MSI-H / BRAF V600E / HER2
Coverage
~35/100k · 3rd most common cancer
Confidence
STRONG
Open Sorries
⚠ KRAS mut = anti-EGFR resistant (40%)
⚠ MSS BRAF V600E poor prognosis
⚠ Peritoneal metastasis no systemic control
HYPOTHESIS
KRAS-wt → cetuximab/panitumumab. BRAF V600E → encorafenib+binimetinib. MSI-H → pembrolizumab 1L.
⚠ OPEN: KRAS G12C/D specific inhibitors — peritoneal disease no durable control
3Sorries
γ₁14.134725141734693
CATAN CANCER · COLORECTAL